Figure 7
From: Comprehensive characterization of TGFB1 across hematological malignancies
Additional value of TGFB1 expression in refining risk stratification in AML. (A) OS and EFS according to TGFB1 expression status among intermediate-risk patients from GSE6891. (B) OS of patients from GSE10358 as stratified by the LI24 and LSC17 score. Patients with a low- and high-risk score were further dichotomized by TGFB1 expression status. The optimal cut-off of TGFB1 was determined by the Maxstat method.
